PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.92%
Negative revenue growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-17.46%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-31.73%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-31.73%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
6.32%
Net income growth of 6.32% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see potential if moderate gains can keep rising.
16.67%
EPS growth of 16.67% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
9.09%
Diluted EPS growth of 9.09% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could improve over time.
8.22%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
6.33%
Diluted share change of 6.33% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
163.13%
OCF growth of 163.13% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
150.08%
FCF growth of 150.08% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
314.91%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.27%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
-45.00%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 11.45%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
8257.32%
OCF/share CAGR of 8257.32% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
66.67%
5Y OCF/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.05%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
133.03%
3Y OCF/share growth > 1.5x Drug Manufacturers - Specialty & Generic median of 1.41%. Joel Greenblatt might see a recent competitive advantage translating into cash improvements.
-1627.18%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 21.03%. Seth Klarman might see a fundamental problem if peers maintain growth.
-333.74%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 19.96%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-256.42%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 26.39%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
7683.64%
Equity/share CAGR of 7683.64% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
181.95%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 0.30%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
18.65%
3Y equity/share CAGR of 18.65% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.79%
AR shrinking while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-1.52%
Decreasing inventory while Drug Manufacturers - Specialty & Generic is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-2.11%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-9.22%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-7.43%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
-0.60%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
4.40%
SG&A growth of 4.40% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.